NL2033322B1 - Baicalin-calcium alginate thermosensitive nanogel as well as preparation method and application thereof - Google Patents

Baicalin-calcium alginate thermosensitive nanogel as well as preparation method and application thereof Download PDF

Info

Publication number
NL2033322B1
NL2033322B1 NL2033322A NL2033322A NL2033322B1 NL 2033322 B1 NL2033322 B1 NL 2033322B1 NL 2033322 A NL2033322 A NL 2033322A NL 2033322 A NL2033322 A NL 2033322A NL 2033322 B1 NL2033322 B1 NL 2033322B1
Authority
NL
Netherlands
Prior art keywords
baicalin
nanogel
calcium alginate
thermosensitive
weight
Prior art date
Application number
NL2033322A
Other languages
English (en)
Other versions
NL2033322A (en
Inventor
Zhang Shanshan
Fan Xiang
Zhou Yuan
Chen Zhong
Original Assignee
Univ Zhejiang Chinese Medical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Zhejiang Chinese Medical filed Critical Univ Zhejiang Chinese Medical
Publication of NL2033322A publication Critical patent/NL2033322A/en
Application granted granted Critical
Publication of NL2033322B1 publication Critical patent/NL2033322B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y40/00—Manufacture or treatment of nanostructures
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Otolaryngology (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • General Physics & Mathematics (AREA)
  • Manufacturing & Machinery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Claims (5)

CONCLUSIES
1. Werkwijze voor het bereiden van thermogevoelige nanogel van baicalin-calciumalginaat, waarbij de thermogevoelige nanogel van baicalin-calciumalginaat wordt bereid uit een actief farmaceutisch ingrediënt baicalin en farmaceutisch effectieve hulpmaterialen, waarbij de werkwijze specifiek de volgende stappen omvat: {1} bereiding van nanogel van baicalin-calciumalginaat het toevoegen van respectievelijk vloeibare paraffine, Span 80 en Tween 80 in een gewichtsverhouding van (500 tot 200):{5 tot 1,5):1, en het volledig dispergeren van het mengsel in een water- bad bij 40 tot 60°C en 500 rpm als een oliefase; het instellen van een roersnelheid op 1000 rpm en het druppelen van 60 tot 300 delen natriumalginaatoplossing die baicaline bevat in de oliefase met een stroomsnelheid van 0,75 ml/min; na voltooiing van het druppe- len, de gemengde oplossing continu roeren totdat de waterfase grondig is gemengd met de oliefase; het toevoegen van 20 tot 100 delen verharder met een stroomsnelheid van 0,25 ml/min onder roe- ren met een snelheid van 1000 rpm; na voltooiing van het druppe- len, het mengsel gedurende 1 uur continu roeren, de resulterende nanogel 15 minuten bij 3.000 rpm centrifugeren, de waterfase af- scheiden om een suspensie van nanogel van baicalin-calciumalginaat te verkrijgen, en snel invriezen met vloeibare stikstof en vries- drogen van de suspensie van nanogel van baicalin-calciumalginaat; waarbij in de natriumalginaatoplossing die baicalin bevat, een na- triumalginaatconcentratie 1 tot 10 mg/ml is, een baicalinconcen- tratie 0,1 tot 20 mg/ml is en de verharder een 70% ethanoloplos- sing van 0,5 tot 5 mg/ml calcium chloride is; (2) bereiding van thermogevoelige nancgel van baicalin- calciumalginaat het toevoegen van normaal zoutoplossing aan 6 gewichtsdelen van nanogel van baicalin-calciumalginaat bereid in S1, het gelijk- matig dispergeren van de nanogel, het toevoegen van 1 gewichtsdeel poloxameer 188 (P 188) en 7 gewichtsdelen poloxameer 407 (P 407) onder ijsbadconditie, en het mengen van het mengsel totdat alle materialen gelijkmatig zijn opgelost om thermogevoelige nanogel van baicalin-calciumalginaat te verkrijgen.
2. Werkwijze voor het bereiden van thermogevoelige nanogel van baicalin-calciumalginaat volgens conclusie 1, waarbij de baicalin- calciumalginaat thermogevoelige nanogel gelatineachtig is bij 30 + 2 °C.
3. Werkwijze voor het bereiden van thermogevoelige nanogel van baicalin-calciumalginaat volgens conclusie 1, waarbij een ge- wichtsverhouding van de vloeibare paraffine tot de Span 80 tot de Tween 80 333,33:2,33:1 is; de hoeveelheid van de natriumalginaat- oplossing die baicaline bevat 100 gewichtsdelen is en de hoeveel- heid verharder 33,33 gewichtsdelen is.
4. Thermogevoelige nanogel van baicalin-calciumalginaat bereid door de bereidingswerkwijze volgens een van de conclusies 1 tot 3.
5. Toepassing van de warmtegevoelige nanogel van baicalin- calciumalginaat volgens conclusie 4 bij het bereiden van een ge- neesmiddel voor de behandeling van een beroerte.
NL2033322A 2021-10-26 2022-10-14 Baicalin-calcium alginate thermosensitive nanogel as well as preparation method and application thereof NL2033322B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202111247965.7A CN113750039B (zh) 2021-10-26 2021-10-26 一种黄芩苷-海藻酸钙温敏纳米凝胶、制备方法及其应用

Publications (2)

Publication Number Publication Date
NL2033322A NL2033322A (en) 2023-05-19
NL2033322B1 true NL2033322B1 (en) 2023-06-21

Family

ID=78784429

Family Applications (1)

Application Number Title Priority Date Filing Date
NL2033322A NL2033322B1 (en) 2021-10-26 2022-10-14 Baicalin-calcium alginate thermosensitive nanogel as well as preparation method and application thereof

Country Status (2)

Country Link
CN (1) CN113750039B (nl)
NL (1) NL2033322B1 (nl)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1127572A3 (en) * 2000-02-25 2003-05-02 Basf Aktiengesellschaft Use of flavones for treating cycloxygenase-2 mediated diseases
CN100554417C (zh) * 2007-12-19 2009-10-28 天津大学 海藻酸-碳酸钙杂化凝胶固定β-葡萄糖醛酸苷酶的方法
CN101732237A (zh) * 2010-01-12 2010-06-16 中国人民武装警察部队医学院 一种黄芩苷温敏凝胶及制备方法和用途
CN102349944B (zh) * 2010-06-01 2014-05-07 四川大千药业有限公司 一种黄芩提取物鼻用温敏型原位凝胶及其制备方法和用途
CN103655482B (zh) * 2012-09-19 2016-05-25 重庆医科大学 用于载药的自微乳化海藻酸钙凝胶微丸及其制备方法
LT3494125T (lt) * 2016-08-02 2022-11-10 Virginia Commonwealth University Kompozicijos, apimančios 5-cholesteną-3, 25-diolį, 3-sulfatą (25hc3s) arba farmaciniu požiūriu priimtiną jo druską ir bent vieną ciklinį oligosacharidą
CN108078915A (zh) * 2018-01-12 2018-05-29 河北科技大学 一种鼻腔给药用温敏原位凝胶
CN111434340B (zh) * 2019-01-11 2022-04-12 天津中医药大学 一种温敏凝胶剂及其制备方法

Also Published As

Publication number Publication date
CN113750039A (zh) 2021-12-07
CN113750039B (zh) 2023-08-18
NL2033322A (en) 2023-05-19

Similar Documents

Publication Publication Date Title
JP6298460B2 (ja) プロゲステロン製剤
CN101066260B (zh) 一种辅酶q10乳剂及其冻干乳剂及制备方法
BRPI0506812B1 (pt) composição base anidra auto-microemulsificável, microemulsão e método de preparação da composição base automicroemulsificável
ES2222581T3 (es) Preparaciones de medicinas para tratar disfuncion sexual.
WO1997020555A1 (en) Treatment or prevention of anoxic or ischemic brain injury with melatonin-containing compositions
TW201818946A (zh) 包含至少一種氧化膽固醇硫酸鹽及至少一種聚烯烴二醇、羧甲基纖維素及聚氧甘油酯之組成物及彼等之使用方法
CN108904522A (zh) 一种肝素衍生物-泊洛沙姆温敏型水凝胶及其制备方法
CN101336890A (zh) 一种抗癌缓释凝胶注射剂
KR101175163B1 (ko) 이소소르비드함유 젤리제제
WO2011047637A1 (zh) 一种含有pH值调节剂的紫杉烷类药物溶液及其制备方法
NL2033322B1 (en) Baicalin-calcium alginate thermosensitive nanogel as well as preparation method and application thereof
CN103816120B (zh) 含有维生素k1的脂肪乳剂
CN102670484B (zh) 甘露糖修饰的固体脂质纳米粒复合凝胶及其制备方法
CN105919949A (zh) 一种稳定的氟比洛芬酯冻干乳及其制备方法
CN103505414B (zh) 丁苯酞滴鼻剂及其制备方法
CN110123757B (zh) 一种应用于治疗脉管异常的乙醇泡沫硬化剂及制备方法
CN1092646A (zh) 含有效成分的冻干乳液
WO2022193975A1 (zh) 供注射用罗哌卡因长效溶液制剂及其制备方法
WO2009135432A1 (zh) 丹酚酸b的抗血栓应用
CN109528632A (zh) 尼莫地平药物组合物、尼莫地平注射液及其制备方法
CN108210929A (zh) 一种含有依托考昔的药物组合物及其制备方法
WO2016119114A1 (zh) 一种葛根素纳米晶胶囊剂及其制备方法
PT1232746E (pt) Composição farmacêutica que compreende goma xantana
RU2705723C1 (ru) Суппозитории ректальные с эритропоэтином, обладающие репаративной и антиоксидантной активностью
CN105796497A (zh) 一种高贮藏稳定性薏苡仁油温敏脂质体的制备方法